Nanogen and Transgenomic in European distribution agreement
US companies Nanogen and Transgenomic have entered into a distribution agreement allowing Transgenomic's European marketing and sales organisation to market, sell and service Nanogen's NanoChip molecular biology workstation in selected western European countries.
US companies Nanogen and Transgenomic have entered into a distribution agreement allowing Transgenomic's European marketing and sales organisation to market, sell and service Nanogen's NanoChip molecular biology workstation in selected western European countries.
The NanoChip Workstation is an automated, open-architecture instrument that facilitates routine detection of known genetic variation, complementing the Transgenomic WAVE System's ability to scan for unknown genetic variation.
Transgenomic has a large, well-established European customer base and the agreement represents an opportunity for Nanogen to expand its market penetration, according to Howard Birndorf, Nanogen's ceo.
'This agreement is part of a strategy of providing total complementary solutions for the genetic research and clinical laboratory markets in Europe,' added Collin D'Silva, Transgenomic's ceo. 'We foresee significant synergy from the addition of the Nanogen platform to our European marketing efforts.'